At the 44th Annual J.P. Morgan Healthcare Conference, CEO and Chairman Joaquin Duato highlighted Johnson & Johnson’s significant outperformance in 2025, citing strong underlying fundamentals that have set the stage for an accelerated growth cycle. Duato noted that J&J expects to exceed 2025’s results in 2026 and is targeting double-digit sales growth in the latter half of the decade. The company is on track to become the largest health care organization globally, with visibility toward surpassing $100 billion in annual sales, underscoring investor confidence in its diversified portfolio across pharmaceuticals, medical devices and consumer health.

Duato outlined three core priorities as J&J enters 2026: deepening R&D investment in oncology and immunology to fuel next-generation drug launches; expanding the surgical robotics and orthopaedics franchises through targeted acquisitions and commercialization partnerships; and optimizing the consumer health segment by accelerating digital initiatives and streamlining supply-chain operations. He emphasized that capital allocation will remain disciplined, with a focus on high-return projects and maintaining the investment-grade credit profile, while continuing to return value to shareholders through regular dividend increases and opportunistic share repurchases.